BII stands for breast implant illness, a term used by patients and clinicians to describe a wide range of systemic symptoms that develop after breast augmentation or reconstruction with implants. It is not a formally recognized medical diagnosis. As of early 2025, the FDA acknowledges that patients report these symptoms but states there are no specific tests or established criteria to define or characterize the condition.
Despite the lack of a formal classification, BII is taken seriously enough that the FDA now requires breast implant manufacturers to include a boxed warning (the strongest type of safety warning) on their labeling. Thousands of patients have reported symptoms, and a growing body of surgical data shows that most people feel significantly better after having their implants removed.
Symptoms of Breast Implant Illness
More than 50 different symptoms have been reported in connection with silicone and saline breast implants. There is no single pattern, which is part of what makes BII so difficult to pin down. The most commonly reported complaints are fatigue, brain fog, anxiety, joint pain, hair loss, and gastrointestinal issues.
Beyond those core symptoms, patients also report chest pain, headaches, chills, sensitivity to light, chronic widespread pain, muscle weakness, dry eyes, dry mouth, skin rashes, sleep problems, depression, neurological symptoms, and hormonal disruptions. The combination and severity vary widely from person to person. Some people develop symptoms within months of getting implants, while others don’t notice problems for years.
What makes BII particularly frustrating is that many of these symptoms overlap with other conditions like fibromyalgia, chronic fatigue syndrome, and autoimmune disorders. People often go through rounds of specialist visits and testing before connecting their symptoms to their implants.
Why It Might Happen
The exact biological mechanism behind BII remains unclear. One leading theory centers on the idea that silicone, even though it’s considered biocompatible, may act as a trigger for the immune system in certain people. Since the 1990s, researchers have observed patients with silicone implants developing a collection of symptoms that don’t neatly fit any recognized connective tissue or autoimmune disorder.
Some of these cases have been linked to a concept called autoimmune syndrome induced by adjuvants, or ASIA. The theory suggests that foreign materials in the body (including silicone) can provoke an immune response that eventually leads to autoimmune-like symptoms. In documented ASIA cases, patients show signs of immune activation such as the production of autoantibodies and tissue inflammation around the implant. However, silicone appears to be a relatively weak immune trigger, meaning only a small subset of people with implants develop this reaction.
What predisposes certain people to BII while others have implants for decades without issue is still unknown. One systematic review found no strong evidence that having a pre-existing autoimmune disease or a family history of autoimmune conditions leads to worse outcomes with breast implants. That said, autoimmune diseases involve both genetic and environmental factors, and the interaction between individual biology and implant materials is likely complex.
How BII Is Evaluated
There is no blood test, imaging study, or diagnostic checklist that can confirm BII. The FDA is clear on this point: no specific tests or recognized criteria exist to define the condition. This means diagnosis is largely a process of exclusion, where doctors rule out other possible causes for a patient’s symptoms before considering the implants as a contributing factor.
A typical workup involves blood tests to check for autoimmune markers, thyroid function, inflammatory levels, and other conditions that could explain the symptoms. If those tests come back normal or inconclusive and the symptoms align with common BII complaints, the conversation often turns to whether implant removal might help. Some clinicians with experience in BII will also evaluate the implant itself through imaging to check for rupture, silicone leakage, or capsular changes, though many BII patients have implants that appear intact on imaging.
What Implant Removal Involves
The primary treatment for BII is explant surgery: removing the breast implants along with the scar tissue capsule that the body naturally forms around them. You’ll often see two terms used in this context. A total capsulectomy means removing the entire scar tissue capsule and the implant. An “en bloc” capsulectomy, a term widely used in patient communities, refers to removing the implant still enclosed within an intact capsule in one piece.
Surgeons have pushed back on the casual use of “en bloc,” noting that the term originates from cancer surgery (specifically for a rare implant-associated lymphoma called BIA-ALCL) and isn’t technically appropriate for non-tumor operations. The more accurate way to describe BII surgery is as a partial or total capsulectomy, with or without keeping the capsule intact around the implant during removal. What matters most for BII patients is that the entire capsule is removed, not just the implant alone.
Recovery and Symptom Improvement
The data on symptom resolution after explant surgery is striking. In one study of patients presenting with BII, 96% reported improved or complete resolution of their systemic symptoms after implant removal combined with total capsulectomy. Even more notable, 90.5% reported a complete disappearance of symptoms. The small percentage of patients (about 4%) who saw no improvement had unremarkable findings on tissue analysis, with no signs of infection, abnormal cells, or fluid around the implant.
Recovery timelines vary. Some patients notice improvements within days or weeks of surgery, particularly with symptoms like brain fog and energy levels. Other issues, such as joint pain, hair regrowth, and hormonal balance, may take several months to resolve. Physical recovery from the surgery itself typically takes a few weeks, though this depends on whether additional procedures like tissue repair or breast lift are performed at the same time.
It’s worth noting that the high improvement rates come from studies of self-selected patients who already believed their implants were causing problems. This makes it difficult to separate the biological effects of implant removal from the psychological relief of taking action. Still, the consistency of improvement across large patient groups suggests something real is happening beyond placebo.
What the FDA Requires Now
The FDA has taken several steps in response to BII reports. Manufacturers are now required to include a boxed warning on breast implant labeling, designed to make sure patients are clearly informed about potential risks before surgery. The agency also recommends that surgeons provide a patient decision checklist covering the known and potential complications of breast implants, including the possibility of systemic symptoms.
These measures stop short of confirming BII as a medical diagnosis, but they represent a significant shift. The FDA continues to collect adverse event reports and monitor ongoing research. For anyone considering breast implants or currently experiencing unexplained symptoms after implant surgery, these regulatory updates mean more information is available upfront than at any previous point.